Key Events This Week
3 Aug: Stock opens at Rs.1,116.25, down 0.91%
4 Aug: Slight recovery to Rs.1,118.50 (+0.20%)
6 Aug: Downgrade to 'Buy' by MarketsMOJO; technical momentum shifts
7 Aug: Week closes at Rs.1,115.20 (+0.81%) but below week open
Aug 07, 03:30 PM
BSE+NSE Vol: 6.82 lacs
3 Aug: Stock opens at Rs.1,116.25, down 0.91%
4 Aug: Slight recovery to Rs.1,118.50 (+0.20%)
6 Aug: Downgrade to 'Buy' by MarketsMOJO; technical momentum shifts
7 Aug: Week closes at Rs.1,115.20 (+0.81%) but below week open

Zydus Lifesciences Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Strong Buy to Buy as of 5 August 2026. This adjustment reflects a nuanced shift in the company’s technical indicators and financial trends, despite its solid long-term fundamentals and market-beating returns.
Read full news article
Zydus Lifesciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a slight dip in daily price, the stock’s long-term indicators remain largely positive, reflecting a complex interplay of momentum and trend signals that investors should carefully consider.
Read full news article
27 Jul: Stock opens at ₹1,108.00 with minor decline amid Sensex rally
28 Jul: Technical momentum signals bullish outlook despite slight price dip
29 Jul: Mixed technical signals as stock dips 0.76%, MarketsMOJO downgrades rating
30 Jul: Upgraded to Strong Buy; stock rallies 2.07% nearing 52-week high
31 Jul: Stock closes week at ₹1,126.50, up 0.99% on strong volume

Zydus Lifesciences Ltd has been upgraded from a Buy to a Strong Buy rating by MarketsMojo as of 29 Jul 2026, reflecting significant improvements in its technical outlook alongside steady fundamental performance. The mid-cap pharmaceutical company’s Mojo Score has risen to 80.0, signalling enhanced investor confidence amid a backdrop of healthy long-term growth and attractive valuation metrics.
Read full news article
Zydus Lifesciences Ltd has demonstrated a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is supported by a confluence of positive signals from key technical indicators including MACD, Bollinger Bands, and moving averages, suggesting an improving price momentum and a favourable outlook for investors in the Pharmaceuticals & Biotechnology sector.
Read full news article
Zydus Lifesciences Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of late July 2026. Despite a slight dip in daily price, the stock continues to demonstrate resilience with mixed signals across key technical indicators such as MACD, RSI, and moving averages, reflecting a complex interplay of market forces within the Pharmaceuticals & Biotechnology sector.
Read full news article
Zydus Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underpinned by positive signals from key technical indicators such as the MACD and moving averages, suggesting a strengthening price momentum despite a marginal dip in the latest trading session.
Read full news article
20 Jul: Stock opens at Rs.1,146.65 with modest gains
22 Jul: Sharp decline to Rs.1,129.75 amid heavy volume
23 Jul: Significant open interest surge despite 1.43% price drop
24 Jul: Mojo Grade downgraded to Buy; technical momentum shifts
Investor Conference
Newspaper publication of notice of loss of share certificate of the Company published in the Financial Express English and Gujarati editions both on August 4 2026.
Investor Conference
11 Aug 2026
Zydus Lifesciences Ltd has declared 100% dividend, ex-date: 24 Jul 26
Zydus Lifesciences Ltd has announced 1:5 stock split, ex-date: 06 Oct 15
Zydus Lifesciences Ltd has announced 1:2 bonus issue, ex-date: 05 Apr 10
No Rights history available